FDA Greenlights Pfizer’s Xalkori for a Rare Form of Non-Hodgkin Lymphoma
On January 15th, Pfizer announced FDA approval for its tyrosine kinase inhibitor, Xalkori, which can be used in pediatric patients one year of age and older and young adults with …
Read More